Screener
Adaptive Biotechnologies ADPT Mrd Business — Adjusted Ebitda
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept adpt:AdjustedEbitda.
The source filing: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:30 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206546
| Line item | Three Months Ended March 31, 2026 / MRD | Three Months Ended March 31, 2026 / Immune Medicine | Three Months Ended March 31, 2026 / Total | Three Months Ended March 31, 2025 / MRD | Three Months Ended March 31, 2025 / Immune Medicine(1) | Three Months Ended March 31, 2025 / Total |
|---|---|---|---|---|---|---|
| Other segment items(2) | — | 5,776 | 5,776 | — | 5,153 | 5,153 |
| Add back: | ||||||
| Items to reconcile net income or net loss to Adjusted EBITDA(3) | 8,776 | 5,569 | 14,345 | 8,127 | 5,813 | 13,940 |
| Adjusted EBITDA(3) | 12,138 | (10,360) | 1,778 | (4,111) | (5,106) | (9,217) |
| Items to reconcile to consolidated net loss: | ||||||
| Share-based compensation expense(4) | (9,969) | (9,654) | ||||
| Restructuring expense(5) | (643) | — | ||||
| Impairment of long-lived assets(5) | (347) | — |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Adaptive Biotechnologies's mrd business — adjusted ebitda?
- Adaptive Biotechnologies (ADPT) reported mrd business — adjusted ebitda of $12.14M in Q1 2026.
- How has Adaptive Biotechnologies's mrd business — adjusted ebitda changed year-over-year?
- Adaptive Biotechnologies's mrd business — adjusted ebitda increased by 395.3% year-over-year, from -$4.11M to $12.14M.
- What is the long-term trend for Adaptive Biotechnologies's mrd business — adjusted ebitda?
- Over 3 years (2022 to 2025), Adaptive Biotechnologies's mrd business — adjusted ebitda has grown at a -36.9% compound annual growth rate (CAGR), from -$60.5M to $15.19M.
- What does mrd business — adjusted ebitda mean?
- This is a non-GAAP measure of the MRD business segment's operating performance, calculated by adding back non-cash and non-recurring expenses to the segment's operating income. It provides a clearer view of the segment's core cash-generating capability by excluding accounting distortions.
Ask your AI about Adaptive Biotechnologies's mrd business — adjusted ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude